David Jesudason

1.8k total citations · 1 hit paper
41 papers, 1.1k citations indexed

About

David Jesudason is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Surgery. According to data from OpenAlex, David Jesudason has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Physiology and 8 papers in Surgery. Recurrent topics in David Jesudason's work include Hormonal and reproductive studies (14 papers), Diet and metabolism studies (9 papers) and Diabetes Treatment and Management (8 papers). David Jesudason is often cited by papers focused on Hormonal and reproductive studies (14 papers), Diet and metabolism studies (9 papers) and Diabetes Treatment and Management (8 papers). David Jesudason collaborates with scholars based in Australia, United Kingdom and United States. David Jesudason's co-authors include Peter Clifton, Gary Wittert, Eva Ringdal Pedersen, Michael Horowitz, Venkatesan Thiruvenkatarajan, Emily J. Meyer, Howard A. Morris, A. G. Need, B. E. C. Nordin and Roelof Van Wijk and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

David Jesudason

37 papers receiving 1.1k citations

Hit Papers

Testosterone treatment to prevent or revert type 2 diabet... 2020 2026 2022 2024 2020 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
    2020 213 citations Gary Wittert, Karen Bracken et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Jesudason Australia 17 600 308 218 149 146 41 1.1k
Tuula Pekkarinen Finland 20 349 0.6× 452 1.5× 274 1.3× 64 0.4× 305 2.1× 33 1.2k
M Medraś Poland 14 368 0.6× 142 0.5× 70 0.3× 49 0.3× 81 0.6× 50 830
J. Lundgren Denmark 16 550 0.9× 596 1.9× 327 1.5× 52 0.3× 207 1.4× 30 1.5k
K Vondra Czechia 21 567 0.9× 289 0.9× 43 0.2× 105 0.7× 103 0.7× 106 1.5k
J. A. Tuominen Finland 20 430 0.7× 510 1.7× 64 0.3× 194 1.3× 210 1.4× 30 1.3k
David Primo Spain 16 258 0.4× 565 1.8× 90 0.4× 56 0.4× 173 1.2× 148 1.1k
Marie S. Thearle United States 22 316 0.5× 971 3.2× 60 0.3× 114 0.8× 188 1.3× 45 1.8k
Francesco Casimirri Italy 24 1.3k 2.1× 582 1.9× 307 1.4× 176 1.2× 126 0.9× 39 2.7k
S. John Weisnagel Canada 19 259 0.4× 469 1.5× 53 0.2× 61 0.4× 235 1.6× 38 1.3k
John T. Devlin United States 19 379 0.6× 605 2.0× 66 0.3× 406 2.7× 119 0.8× 32 1.2k

Countries citing papers authored by David Jesudason

Since Specialization
Citations

This map shows the geographic impact of David Jesudason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jesudason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jesudason more than expected).

Fields of papers citing papers by David Jesudason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Jesudason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jesudason. The network helps show where David Jesudason may publish in the future.

Co-authorship network of co-authors of David Jesudason

This figure shows the co-authorship network connecting the top 25 collaborators of David Jesudason. A scholar is included among the top collaborators of David Jesudason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Jesudason. David Jesudason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vincent, Andrew, et al.. (2025). The effect of obesity interventions on male fertility: a systematic review and meta-analysis. Human Reproduction Update. 32(2). 154–180.
2.
3.
Umapathysivam, Mahesh M., Sameena Nawaz, Kristy Robledo, et al.. (2024). 7700 Two Years Of Testosterone Therapy Reduces Glycemia In Males At High Risk Of Type 2 Diabetes Without Affecting Beta Cell Function: Results From A Randomised Controlled Trial And Cellular Model. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations
4.
Grossmann, Mathis, Kristy Robledo, Mark Daniel, et al.. (2024). Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 109(8). 2019–2028. 6 indexed citations
5.
Umapathysivam, Mahesh M., et al.. (2024). SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis. JAMA Network Open. 7(3). e242744–e242744. 8 indexed citations
6.
Vincent, Andrew, et al.. (2024). Impact of bariatric surgery, lifestyle change, and pharmacotherapy on fertility in men with obesity: a systematic review protocol. JBI Evidence Synthesis. 22(7). 1393–1400. 1 indexed citations
7.
8.
Robledo, Kristy, Ian C. Marschner, David J. Handelsman, et al.. (2023). Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial. European Journal of Endocrinology. 189(1). 50–57. 15 indexed citations
9.
10.
Thiruvenkatarajan, Venkatesan, et al.. (2022). Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence. Canadian Journal of Diabetes. 47(3). 287–291. 3 indexed citations
11.
Wittert, Gary, Karen Bracken, Kristy Robledo, et al.. (2020). Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The Lancet Diabetes & Endocrinology. 9(1). 32–45. 213 indexed citations breakdown →
12.
Bracken, Karen, Wendy Hague, Anthony Keech, et al.. (2019). Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies. Trials. 20(1). 366–366. 24 indexed citations
13.
Thiruvenkatarajan, Venkatesan, et al.. (2019). Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. British Journal of Anaesthesia. 123(1). 27–36. 106 indexed citations
14.
Jesudason, David, Eva Ringdal Pedersen, & Peter Clifton. (2013). Weight-loss diets in people with type 2 diabetes and renal disease: a randomized controlled trial of the effect of different dietary protein amounts. American Journal of Clinical Nutrition. 98(2). 494–501. 59 indexed citations
15.
Pedersen, Eva Ringdal, David Jesudason, & Peter Clifton. (2013). High protein weight loss diets in obese subjects with type 2 diabetes mellitus. Nutrition Metabolism and Cardiovascular Diseases. 24(5). 554–562. 27 indexed citations
16.
Jesudason, David, BE Christopher Nordin, Jennifer Keogh, & Peter Clifton. (2013). Comparison of 2 weight-loss diets of different protein content on bone health: a randomized trial. American Journal of Clinical Nutrition. 98(5). 1343–1352. 35 indexed citations
17.
Jesudason, David & Gary Wittert. (2008). Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology. 19(4). 344–348. 35 indexed citations
18.
Neary, Nicola M., Barbara McGowan, Mariana P. Monteiro, et al.. (2008). No evidence of an additive inhibitory feeding effect following PP and PYY3−36 administration. International Journal of Obesity. 32(9). 1438–1440. 28 indexed citations
19.
Jesudason, David, Mariana P. Monteiro, Barbara McGowan, et al.. (2007). Low-dose pancreatic polypeptide inhibits food intake in man. British Journal Of Nutrition. 97(3). 426–429. 65 indexed citations
20.
Jesudason, David, A. G. Need, Michael Horowitz, et al.. (2002). Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency. Bone. 31(5). 626–630. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tuula Pekkarinen Breakdown of academic impact, for papers by M Medraś Breakdown of academic impact, for papers by J. Lundgren Breakdown of academic impact, for papers by K Vondra Breakdown of academic impact, for papers by J. A. Tuominen Breakdown of academic impact, for papers by David Primo Breakdown of academic impact, for papers by Marie S. Thearle Breakdown of academic impact, for papers by Francesco Casimirri Breakdown of academic impact, for papers by S. John Weisnagel Breakdown of academic impact, for papers by John T. Devlin
Rankless by CCL
2026